Actually, it is the opposite in terms of sales. Elekta's net sales growth in 2024 was up +12% and that is in an environment of higher interest rates for financing.

The Mridian had financial problems, not because of sales but because Scott Blake, the President, did not manage his cash flow and receivables in a timely manner. Sales were strong.

Your right, it takes one extra person, which I perceive as an extra set of eyes, to run the Mri machines. Institutions, even centers of excellence, have to manage these machines in a way that gives them the same ROI as other non-mri radiation machines. They should manage it better because it is better for the cancer patient. It is their job to triage machines and patient needs to achieve an ROI and satisfy the patient. Some do it better than others. When I asked the head of a oncology department of a Center of Excellence whether they would be using the dynamic capability features of the Mridian to treat me, his answer was "if you want to use that feature, you may want to go someplace else." I went someplace else.

We all know how complicated the decisions are for treatment in terms of monies spent whether it is socialized medicine or capitalism medicine but all institutions should, have as its primary directive, to provide the best that is available and manage the costs accordingly. Of course, one institutions manageable costs is another's nightmare.

The Mirage randomized trial proved that lower margins reduced toxicity and side effects with radiation machines that had built in MRI so as a patient, that's what I did and would do it again and I sincerely hope the MRI based machines continue to become more available.